Literature DB >> 27638973

Increased risk of chronic liver disease in patients with bipolar disorder: A population-based study.

Jer-Hwa Hsu1, I-Chia Chien2, Ching-Heng Lin3.   

Abstract

OBJECTIVE: This study aimed to investigate the prevalence and incidence of chronic liver disease in patients with bipolar disorder.
METHODS: We used a random sample of 766,427 subjects aged ≥18 years from the National Health Research Institute database in the year 2005. Subjects with at least one primary diagnosis of bipolar disorder in 2005 were identified. Patients with a primary or secondary diagnosis of chronic liver disease were also defined. We compared the prevalence and associated factors of chronic liver disease between patients with bipolar disorder and the general population in 2005. We also compared the incidence of chronic liver disease in patients with bipolar disorder and the general population from 2006 to 2010.
RESULTS: The prevalence of chronic liver disease in patients with bipolar disorder (13.9%) was 2.68 times higher than that of the general population (5.8%) in 2005. The average annual incidence of chronic liver disease in patients with bipolar disorder from 2006 to 2010 was also higher than that of the general population (2.95% vs. 1.73%; risk ratio: 1.71; 95% confidence interval: 1.46-2.01).
CONCLUSIONS: Patients with bipolar disorder had a significantly higher prevalence and incidence of chronic liver disease than those in the general population, and younger patients with bipolar disorder have a much higher prevalence and incidence than those in the general population. Male sex, second-generation antipsychotic or antidepressant use, and hyperlipidemia were associated factors for chronic liver disease in patients with bipolar disorder.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesic; Bipolar disorder; Chronic liver disease; National Health Insurance; Prevalence; Taiwan

Mesh:

Year:  2016        PMID: 27638973     DOI: 10.1016/j.genhosppsych.2016.07.006

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  10 in total

Review 1.  Behavioral health disorders related to nonalcoholic steatohepatitis.

Authors:  Aadi Sharma; Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-16

2.  Outcomes of Hospitalized Acute Alcoholic Hepatitis (AH) in Patients With Bipolar 1 Disorder (B1D).

Authors:  Alexander J Kaye; Shivani Patel; Sarah Meyers; Daniel Rim; Catherine Choi; Sushil Ahlawat
Journal:  Cureus       Date:  2022-05-27

3.  Management of Psychiatric Disorders in Patients with Hepatic and Gastrointestinal Diseases.

Authors:  Vikas Menon; Ramdas Ransing; Samir Kumar Praharaj
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

4.  Increased expression of soluble epoxide hydrolase in the brain and liver from patients with major psychiatric disorders: A role of brain - liver axis.

Authors:  Jiancheng Zhang; Yunfei Tan; Lijia Chang; Bruce D Hammock; Kenji Hashimoto
Journal:  J Affect Disord       Date:  2020-04-08       Impact factor: 4.839

5.  Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis.

Authors:  B Yang; Q Ren; J-C Zhang; Q-X Chen; K Hashimoto
Journal:  Transl Psychiatry       Date:  2017-05-16       Impact factor: 6.222

6.  Restraint Stress in Mice Alters Set of 25 miRNAs Which Regulate Stress- and Depression-Related mRNAs.

Authors:  Joanna Solich; Maciej Kuśmider; Agata Faron-Górecka; Paulina Pabian; Marta Dziedzicka-Wasylewska
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

7.  Mood disorders, childhood maltreatment, and medical morbidity in US adults: An observational study.

Authors:  Emma K Stapp; Stacey C Williams; Luther G Kalb; Calliope B Holingue; Kathryn Van Eck; Elizabeth D Ballard; Kathleen R Merikangas; Joseph J Gallo
Journal:  J Psychosom Res       Date:  2020-07-28       Impact factor: 3.006

Review 8.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

9.  Serum Level of miR-1 and miR-155 as Potential Biomarkers of Stress-Resilience of NET-KO and SWR/J Mice.

Authors:  Joanna Solich; Maciej Kuśmider; Agata Faron-Górecka; Paulina Pabian; Magdalena Kolasa; Beata Zemła; Marta Dziedzicka-Wasylewska
Journal:  Cells       Date:  2020-04-09       Impact factor: 6.600

Review 10.  Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches.

Authors:  Óscar Soto-Angona; Gerard Anmella; María José Valdés-Florido; Nieves De Uribe-Viloria; Andre F Carvalho; Brenda W J H Penninx; Michael Berk
Journal:  BMC Med       Date:  2020-10-01       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.